Skip to search formSkip to main contentSkip to account menu

JNJ 10198409

Known as: JNJ-10198409, JNJ10198409 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.
Extensive first-pass metabolism can significantly limit a drug's oral exposure levels. In this work, we introduce an innovative… 
2006
2006
N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP…
The potential cancer therapeutic agent, 6,7-(dimethoxy-2, 4-dihydroindeno[1,2-c]pyrazol-3-yl)-(3-fluoro-phenyl)-amine (JNJ… 
2006
2006
DMD # 9274 1 N-Glucuronidation of the PDGF Receptor Tyrosine Kinase Inhibitor 6 , 7-( Dimethoxy-2 , 4-dihydroindeno [ 1 , 2-c ] pyrazol-3-yl )-( 3-fluoro-phenyl )-amine by Human UDP…
The potential cancer therapeutic agent, 6,7-(dimethoxy-2,4-dihydroindeno[1,2c]pyrazol-3-yl)-(3-fluoro-phenyl)-amine (JNJ-10198409… 
2005
2005
Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis
With the advent of agents directed against specific molecular targets in drug discovery, it has become imperative to show a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)